Publication
Article
Pharmacy Times
The appetite for generic drugsthroughout the European Communityis expected to double in thenext 7 years, jumping from $17.18billion in 2006 to nearly $36 billionby 2013, according to a new marketanalysis by Frost & Sullivan. As inthe United States, rising health costs in Europe are causinggovernment leaders to explore methods for promotingincreased use of more cost-effective generic medicines, thestudy noted.
?Patent expiries, pro-generic reforms in certain countries,and need for cheap, effective medicines are the key factorsdriving growth in the European generics market,? a researcherfor the company explained. ?Various studies haveindicated the cost savings obtained from generics, and severalgovernments in Europe are actively promoting generics.?
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.